Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?

被引:197
作者
Peyrin-Biroulet, Laurent [1 ,2 ]
Bressenot, Aude [1 ,3 ]
Kampman, Wendy [4 ]
机构
[1] INSERM, U954, F-75654 Paris 13, France
[2] Univ Henri Poincare, Univ Hosp Nancy, Dept Hepatogastroenterol, Vandoeuvre Les Nancy, France
[3] Univ Henri Poincare, Univ Hosp Nancy, Dept Pathol, Vandoeuvre Les Nancy, France
[4] Bristol Myers Squibb Co, Princeton, NJ USA
关键词
Inflammatory Bowel Disease; Histologic Assessment; Disease Modification; COLORECTAL NEOPLASIA; ACTIVITY INDEXES; CLINICAL-TRIALS; RISK-FACTOR; INFLAMMATION; BUDESONIDE; PREDICTORS; SEVERITY; EFFICACY; RELAPSE;
D O I
10.1016/j.cgh.2013.07.022
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Ulcerative colitis (UC) is a disease of the mucosal layer, and activity of the disease is assumed to be related to mucosal appearance. Mucosal healing has emerged as a major therapeutic goal in UC. Whether mucosal healing should be the ultimate therapeutic goal in these patients is unknown. Even when endoscopy suggests mucosal healing, evidence of histologic activity has been observed. Histologic healing requires complete recovery of the colonic mucosa, with absence of inflammation or structural changes. Histologic improvements have been linked with improved clinical outcomes, such as a reduced risk of relapse and need for surgery/hospitalization and a reduced risk of developing cancer. Hence, there is a rationale for aiming for histologic remission in UC. Numerous methods of classification of histologic activity in UC have been proposed, although only some of these are widely used. We review the current definitions of histologic remission, the range of scoring systems most commonly used, and the evidence of histologic improvement that is available from the latest therapies for UC. We also highlight questions that will require careful consideration if histologic remission is to become more widely used as an end point in clinical trials and a treatment goal in clinical practice.
引用
收藏
页码:929 / +
页数:8
相关论文
共 43 条
[1]
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis [J].
Ardizzone, Sandro ;
Cassinotti, Andrea ;
Duca, Piergiorgio ;
Mazzali, Cristina ;
Penati, Chiara ;
Manes, Gianpiero ;
Marmo, Riccardo ;
Massari, Alessandro ;
Molteni, Paola ;
Maconi, Giovanni ;
Porro, Gabriele Bianchi .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (06) :483-U117
[2]
Biological and Histological Parameters as Predictors of Relapse in Ulcerative Colitis: A Prospective Study [J].
Azad, Sheenam ;
Sood, Neena ;
Sood, Ajit .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2011, 17 (03) :194-198
[3]
Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing [J].
Bessissow, Talat ;
Lemmens, Bart ;
Ferrante, Marc ;
Bisschops, Raf ;
Van Steen, Kristel ;
Geboes, Karel ;
Van Assche, Gert ;
Vermeire, Severine ;
Rutgeerts, Paul ;
De Hertogh, Gert .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) :1684-1692
[4]
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis [J].
Bitton, A ;
Peppercorn, MA ;
Antonioli, DA ;
Niles, JL ;
Shah, S ;
Bousvaros, A ;
Ransil, B ;
Wild, G ;
Cohen, A ;
Edwardes, MDD ;
Stevens, AC .
GASTROENTEROLOGY, 2001, 120 (01) :13-20
[5]
Burger DC., 2011, J CROHNS COLITIS, V5, pS4
[6]
Infliximab for patients with refractory ulcerative colitis [J].
Chey, WY .
INFLAMMATORY BOWEL DISEASES, 2001, 7 :S30-S33
[7]
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis [J].
Colombel, Jean Frederic ;
Rutgeerts, Paul ;
Reinisch, Walter ;
Esser, Dirk ;
Wang, Yanxin ;
Lang, Yinghua ;
Marano, Colleen W. ;
Strauss, Richard ;
Oddens, Bjoern J. ;
Feagan, Brian G. ;
Hanauer, Stephen B. ;
Lichtenstein, Gary R. ;
Present, Daniel ;
Sands, Bruce E. ;
Sandborn, William J. .
GASTROENTEROLOGY, 2011, 141 (04) :1194-1201
[8]
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation [J].
Cooney, Rachel M. ;
Warren, Bryan F. ;
Altman, Douglas G. ;
Abreu, Maria T. ;
Travis, Simon P. L. .
TRIALS, 2007, 8 (1)
[9]
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis [J].
D'Haens, Geert ;
Sandborn, William J. ;
Feagan, Brian G. ;
Geboes, Karel ;
Hanauer, Stephen B. ;
Irvine, E. Jan ;
Lemann, Marc ;
Marteau, Philippe ;
Rutgeerts, Paul ;
Scholmerich, Jurgen ;
Sutherland, Lloyd R. .
GASTROENTEROLOGY, 2007, 132 (02) :763-786
[10]
PERSISTENCE OF MUCOSAL ABNORMALITY IN ULCERATIVE COLITIS [J].
DICK, AP ;
HOLT, LP ;
DALTON, ER .
GUT, 1966, 7 (04) :355-&